| abstract |
The present invention relates to a novel CCR2 antagonist and its use. Specifically, the invention relates to application of a compound shown in the formula I or pharmaceutically acceptable salt thereof in preparing a medicament or reagent for regulating a tumor microenvironment, reducing recruitment of macrophages and bone marrow cells to a primary tumor, inhibiting tumor growth, inhibiting angiogenesis and/or increasing CD8T cells in a subject in need thereof, application in preparing a medicament for treating or preventing a CCR 2-mediated disease of the subject, or application in preparing a medicament or reagent for inhibiting CCR2 or CCL2-CCR2 pathway, wherein a, b, c, d, R and R are shown in the formula 1 、R 2 、R 3 And R 4 As described herein. |